Biological drug duo delivers one-two tumor punch

Nature Medicine

Volumn 9, Issue 6, 2003, Pages 649-650

  Sosman, Jeffrey A ^a   Mier, James W ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MANGANESEDICHLORO(3,10,13,20,26 PENTAAZATETRACYCLO[20.3.1.0(4,9).0(14,19)] 1(26),22(23),24 HEXACOSATRIENE); RETINOIC ACID; RETINOID; VASCULOTROPIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER MODEL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOXICITY; HUMAN; KIDNEY CANCER; MELANOMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SHORT SURVEY; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MELANOMA; MICE; ORGANOMETALLIC COMPOUNDS; SUPEROXIDES; SURVIVAL RATE;

EID: 0037630078     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0603-649     Document Type: Short Survey

References (12)

1. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
2. Atkins, M.B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105-2116 (1999).
3. Samlowski, W.E. et al. A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat. Med. 9. 750-755 (2003).
4. Salvemini, D. et al. A nonpeptidyl mimic of super-oxide dismutase with therapeutic activity in rats. Science 286, 304-306 (1999).
5. Macarthur, H., Westfall, T.C., Riley, D.P., Misko, T.P. & Salvemini, D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc. Natl. Acad. Sci. USA 97, 9753-9758 (2000).
6. Mier, J.W. & Atkins, M.B. Mechanisms of action and toxicity of immunotherapy with cytokines. Curr. Opin. Oncol. 5, 1067-1072 (1993).
7. Hibbs, J.B. Jr. et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J. Clin. Invest. 89, 867-877 (1992).
8. Dubois, J. et al. Randomized placebo-controlled clinical trial of high dose interleukin-2 in combination with soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J. Clin. Oncol. 15, 1052-1061 (1997).
9. McDermott, D. et al. A two-part phase I trial of high dose interleukin-2 in combination with soluble Chinese hamster ovary IL-1 receptor. Clin. Cancer Res. 5, 1203-1213 (1998).
10. Margolin, K. et al. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma. Clin. Cancer Res. 3, 565-572 (1997).
11. + myeloid cells. J. Immunol. 166, 5398-5406 (2001).
12. Gabrilovich, D.I., Ishida, T., Nadaf, S., Ohm, J.E. & Carbone, D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999).